RNS Number : 5073X
Pharma C Investments PLC
20 December 2023

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

20 December 2023

Pharma C Investments PLC

("Pharma C" or the "Company")

Publication of Accounts

Pharma C (AQSE: PCIL) is pleased to announce the publication of its audited financial statements for the year ended 31 December 2022 which are available to view and download from the Investor Relations section of the Company's website at https://www.pharmacinvestments.com/investors/reports-presentations. The Company will call its Annual General Meeting in due course.

The Directors of Pharma C take responsibility for this announcement.

For further information please visit www.pharmacinvestments.com

Pharma C Investments	
Gavin Sathianathan	Via First Sentinel
First Sentinel Corporate Finance	
Brian Stockbridge, Corporate Adviser	+44 20 3855 5551

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFEAFLSEDSESE